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Experience of an Infectious Diseases (ID) Travel Medicine Clinic During a 
National Shortage of Yellow Fever Vaccine (YFV)
Mark C. Knouse, MD, Terri I. Langham RN, Marcelo Gareca, MD and Jarrod W. Kile, RPh 
Lehigh Valley Health Network, Allentown, Pa.
BACKGROUND
In April 2017, Sanofi Pasteur (SP), the sole supplier of Yellow Fever Vaccine (YFV) 
in the US, announced that supplies of YFV would be temporarily unavailable in the 
US. In conjunction with the FDA, SP launched an Expanded Access IND Program 
(EAP), to allow importation of YFV produced in France (Stamaril) by Sanofi Pasteur. 
Approximately 250 sites in the US were chosen based on geography, volume, and 
other factors. Our clinic, located in Eastern PA, was selected as one of those sites. 
OBJECTIVE
To review our clinic’s experience with the Stamaril EAP and to evaluate tolerance/
adverse effects in our practice. 
METHODS
Our travel clinic is a medium-sized clinic that is em bedded within a 14 Physician ID 
practice. We performed a 17-month review of Stamaril usage at our clinic. 
RESULTS
Our physicians had to complete SP training, CITI (research ethics and compliance) 
training, and our own internal training before being able to prescribe Stamaril. 
Through 4/30/19, our clinic has administered 1,129 Stamaril doses, of which 844 
were administered in 2018. Clinic visit volumes increased from 718 unique visits in 
2017 to 1,402 in 2018 (95% increase). “Stamaril only” visits were 333 (24%) of 
total travel visits for 2018. Traveler’s came from multiple states outside our 
catchment area. We documented 3 serious adverse events (SAE) whether or not 
considered related to the vaccine. One was a CDC confirmed case of Yellow Fever 
vaccine-associated neurotrophic disease (YEL-AND) in a 70-year-old male (fully 
recovered), another was new-onset generalized seizures (not confirmed as  
YEL-AND, fully recovered) in a 55-year-old male. The third was a Brighton Level 1 
for diagnostic criteria and probable case for vaccine causality of Viscerotrophic 
disease (VTD) in a 65-year-old male (recovering). To accommodate increased 
volumes, we added 1 physician, and 1 Physician Assistant-Certified (PAC) to our 
travel rotations – 2 more providers are in training. We held 8 evening sessions to 
accommodate larger groups in need of YFV. 
CONCLUSION
Participation in the Stamaril EAP program greatly increased our travel clinic 
volumes resulting in a need to add providers and extra hours to absorb demand. 
There were 3 serious adverse events (0.26%): 1 of which was confirmed to be 
YEL-AND and one probable for VTD for vaccine causality. 
DEFINITIONS
1.  SAE: Serious Adverse Event: Any Stamaril recipient who  
was hospitalized, died, or had serious continued health problem 
whether or not considered related to the vaccine (6-week 
window).
2.  YEL-AND: Yellow Fever Vaccine Associated Neurologic Disease
3.  YEL-AVD: Yellow Fever Vaccine Associated Viscerotrophic Disease
4.  VTD: Viscerotrophic Disease, by Brighton Classification
5.  SP: Sanofi Pasteur
6.  YFV: Yellow Fever Vaccine
TWO MAJOR WORKING GROUP SYSTEMS FOR CLASSIFICATION OF  
SERIOUS YFV REACTIONS
CDC definition of a Yellow Fever Adverse Reactions1
YEL-AND: includes Level 1,2 clinical criteria for 
ascertainment and assignment to Suspect, 
Probable, and Definite case definitions for  
YFV-AND based on virologic data (including  
YF 17D PCR in CSF/Serum, CSF IgM assay,  
PRNT assay.
YEL-AAD-CNS or YEL-AAD-PNS: categories for Yellow Fever 
Vaccine Associated Autoimmune Disease with CNS involvement.
YEL-AVD: Includes Level 1,2 clinical criteria for case 
ascertainment and assignment to Suspect, Probable, and  
Definite case definitions for YEL-AVD based on Liver  
dysfunction, 17-D virus PCR in serum, tissue, or detection  
of YF virus antigen by IHC in tissue. 
BRIGHTON CLASSIFICATION FOR  
YEL-AVD
Developed in conjunction with WHO to define Yellow Fever 
Viscerotrophic Disease (VTD)2
Includes Case Definitions with Major and Minor 
criteria with thresholds and assignment to Vaccine-
associated causality as Suspect, Probable, and 
Definite based on 17-D virus by PCR in blood, 
tissue histology, and also isolation of virus from 
tissue by IHC or PCR.
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SUMMARY
A nation-wide shortage of US produced yellow fever vaccine 
starting in 2017 has greatly changed our travel practice outpatient 
volumes – nearly doubling over one year. This has greatly 
changed the dynamics of our practice. Volumes continue to rise 
relative to general ID visits.
Staffing and ultimately our business plan for the future will continue 
to evolve as the EAP continues or ends. Based on our experience, 
travel clinics will need to find ways to plan and implement rapid 
changes in staffing plans for future vaccine shortages.
SAEs tended to occur in older travelers (mean age 64) and were 
seen only in males. Our numbers of SAE (3=0.26%) were 
numerically higher than previously published rates.1,4 The reasons 
for this are not known but might be in part due to chance with 
relatively low visit volumes of a single travel clinic. 
Enhanced safety surveillance may also have played a role in higher 
SAE rates, owing to the increased vigilance required of an IRB-
approved EAP. Our observations agree with SP and FDA’s 
ongoing assessment of all adverse events, including SAEs for this 
EAP, continued SP and FDA review is appropriate. All clinics 
involved in future EAP will need to carefully monitor patient 
adverse events and rapidly report any significant events in 
accordance with the EAP guidelines and IRB requirements.
TABLE 4: SAE CASE REPORTS






Admitted with fever, Headache 
and ataxia, 15 days after 
vaccination. LP with 146 WBC  






onset seizure – 
not confirmed as 
YEL-AND
Admitted with 2 generalized 
seizures within 2 weeks of YFV 
CSF: No pleocytosis, Protein 77.  
MRI Neg YFV PCR/IgM/PRNT  
all neg 
Fully recovered 









Admitted with fever, malaise, 
diarrhea, AKI, Thrombocytopenia 
(Platelet nadir=64,000), increased 
LFTs (T bilirubin peak=2.0). Blood 
YFV 17D PCR + day 5 (2-3 log10 
pfu/ml). PCR negative (day 14) 
C-diff + PCR
Creatinine  
peak of 8.2 
with decrease 




TABLE 1: TRAVEL CLINIC VOLUME IMPACT
Year
Travel Visits  
(% increase 
from prior year)
Stamaril Only Visits 





2017 (pre-Stamaril) 718 (N/A) 5 (N/A) (N/A)
2018 (All Stamaril) 1402 (95%) 333 (N/A) 1459/4903 (30%)
2019 (Thru April 30) 504 (8%*) 266 (239%*) 504/1301 (39%*)
Total  (N/A) 604  (N/A)
*Estimated percentage extrapolated from 4 months of data to full calendar year.










TABLE 3:  
STAFFING CHANGES
















*  Additional shifts added for nursing staff.
TRAVEL CLINIC STAFFING IMPACT
•  Additional physician and PA-C providers were added/trained to absorb demand
•  Required training included CITI training, Sanofi Pasteur Stamaril training, and Division travel 
provider onboarding (mentoring-based).
•  For 2018, we held 8 evening clinic sessions (Up to 12 travelers per session).
TRAVEL CLINIC VISIT VOLUMES
•  Participation in the Stamaril EAP program greatly increased our travel clinic visit volumes from 
718 (2017) to 1,402 (2018) to projected 1,512 (2019) (See table 1+ 2)
	 n  Our Travel Clinic visit volumes continue to increase
	 n  Travel Visits to ID Visit ratio continues to rise
	 n  Stamaril only visits numbered 604 since implementation
ADVERSE EVENTS
•  There were three Serious Adverse Events (All hospitalizations) for an SAE rate of 0.26% 
(through April 30,2019)
	 n  One of which was confirmed to be YEL-AND, one probable YEL-AVD*, and one seizure 
(unknown relationship). 
 * Clinical criteria confounded by positive Clostridium difficile PCR in stool (patient felt to be colonized).
	 n  All three patients were hospitalized and all three have been discharged. 
	 n  Two are fully recovered and the most recent patient (YEL-AVD) continues to recover. 
	 n  No other adverse events were encountered which were deemed to be vaccine related 
based on ID physician’s clinical judgment. 
